Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the gross margin high or low?
The gross margin of 88.90% is in line with its 3-year average of 86.38%, around the middle of its 3-year range (83.77%–92.32%).
0.27% above its 12-month average of 88.66%.
Reported quarterly gross margin; no daily interpolation. Q2 FY2026 (2026-06-30): 92.32%.
GROSS MARGIN
88.90%
GROSS MARGIN AVG TTM
88.66%
GROSS MARGIN AVG 3Y
86.53%
GROSS MARGIN AVG 5Y
N/A
GROSS MARGIN AVG 10Y
N/A
GROSS MARGIN AVG 15Y
N/A
GROSS MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
+0.27%
CURRENT VS 3Y AVG
+2.73%
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
46.60%
median of 388 covered companies
CURRENT VS SECTOR MEDIAN
+90.77%
vs the sector median at left
Market Cap
$922.50M
Gross Margin
99.98%
TTM Avg
98.71%
3Y Avg
99.36%
5Y Avg
-14.89%
Market Cap
$903.13M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$985.79M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
16.67%
Market Cap
$989.05M
Gross Margin
100.00%
TTM Avg
100.00%
3Y Avg
50.00%
5Y Avg
50.00%
Market Cap
$867.60M
Gross Margin
92.94%
TTM Avg
91.25%
3Y Avg
45.63%
5Y Avg
30.42%
Market Cap
$852.55M
Gross Margin
58.31%
TTM Avg
55.25%
3Y Avg
65.77%
5Y Avg
65.77%
| NAME | MARKET CAP | GROSS MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| CeriBell, Inc. (CBLL) | $943.26M | 88.90% | 88.66% | 86.53% | N/A |
| Arbutus Biopharma Corp (ABUS)vs › | $922.50M | 99.98% | 98.71% | 99.36% | -14.89% |
| Bioventus Inc. (BVS)vs › | $915.95M | 68.00% | 67.52% | 65.94% | 67.78% |
| Corvus Pharmaceuticals, Inc. (CRVS)vs › | $903.13M | 0.00% | 0.00% | 0.00% | 0.00% |
| Cullinan Therapeutics, Inc. (CGEM)vs › | $985.79M | 0.00% | 0.00% | 0.00% | 16.67% |
| Aktis Oncology, Inc. (AKTS)vs › | $989.05M | 100.00% | 100.00% | 50.00% | 50.00% |
| Monte Rosa Therapeutics, Inc. (GLUE)vs › | $867.60M | 92.94% | 91.25% | 45.63% | 30.42% |
| Apnimed, Inc. (APMD)vs › | $866.15M | N/A | N/A | N/A | N/A |
| Beta Bionics, Inc. (BBNX)vs › | $852.55M | 58.31% | 55.25% | 65.77% | 65.77% |
| Alumis Inc. (ALMS)vs › | $844.28M | 88.23% | 42.73% | 21.36% | 21.36% |
Gross Margin
88.9%
(Revenue - COGS) / Revenue
Gross Margin = Gross Profit / Revenue
Gross margin is the percentage of revenue remaining after the cost of goods sold, reflecting core product profitability.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | GROSS MARGIN |
|---|---|
| 2026-06-30 | 92.32% |
| 2026-03-31 | 87.27% |
| 2025-12-31 | 87.33% |
| 2025-09-30 | 88.28% |
| 2025-06-30 | 88.13% |
| 2025-03-31 | 87.88% |
| 2024-12-31 | 87.61% |
| 2024-09-30 | 87.30% |
| 2024-06-30 | 85.82% |
| 2024-03-31 | 85.82% |
| 2023-12-31 | 84.65% |
| 2023-09-30 | 83.77% |
| 2023-06-30 | 84.56% |
| 2023-03-31 | 84.56% |
